ReviewTheranostics2022
Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review.
Review in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
116 citing papers in PubMed, 2 syntheses or guidelines pooled it, 188 citations in OpenAlex.
- Performance of fibroblast activating protein inhibitor PET imaging for pancreatic neoplasms assessment: a systematic review and meta-analysis.European radiology · 2024Pooled it
- [European journal of medical research · 2023Pooled it
- Same-day dual-tracer PET/CT imaging with [Annals of nuclear medicine · 2025Trial
- Fibroblast activation protein-targeted PET/CT withEuropean journal of nuclear medicine and molecular imaging · 2025Trial
- [European journal of nuclear medicine and molecular imaging · 2025Trial
- Preclinical evaluation of homodimeric FAPI target modules for UniCAR-mediated targeting of FAP-expressing tumor and stromal cells.Oncoimmunology · 2026Article
- Diagnostic value of [Abdominal radiology (New York) · 2026Article
- The value ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Superiority of [Annals of surgical oncology · 2026Article
- Comparison of PET imaging of [18F]F-FAPI and [18F]F-FDG for diagnosis of suspected lymph node metastases in penile squamous cell carcinoma: a prospective pilot study.European journal of nuclear medicine and molecular imaging · 2026Article
- FAPI Dimerization for Theranostic Applications: Molecular Design, Preclinical Validation, and Clinical Translation.Chemical & biomedical imaging · 2026Review
- Serum FAP⁺ exosome-based flow cytometric detection: potential utility in early diagnosis, disease progression assessment, and surgical response monitoring of lung adenocarcinoma.Journal of nanobiotechnology · 2026Article
- Diagnostic Performance ofNPJ breast cancer · 2026Article
- [Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Reprogramming Antitumor Immunity: NK Cell Strategies to Navigate the Immunosuppressive Tumor Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Noninvasive tracking of myocardial fibrosis in pressure-overload heart failure with [EJNMMI research · 2026Article
- Nanomaterials targeting cancer-associated fibroblasts to overcome stromal barriers in cancer immunotherapy.Journal of nanobiotechnology · 2026Review
- Review
- Differential [European journal of nuclear medicine and molecular imaging · 2026Article
- Comparative evaluation of [European journal of nuclear medicine and molecular imaging · 2026Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, quinoline-based fibroblast activation protein (FAP) inhibitors (FAPI) have shown promising results in the diagnosis of cancer and several other diseases, making them the hotspot of much productive research. This review summarizes the literature for the state-of-the-art FAPI-PET imaging for cancer diagnosis compared with fluorodeoxyglucose (FDG)-PET. We also summarize the use of FAPI-PET for therapeutic regimen improvement and fibroblast activation protein (FAP)-targeted molecule modification strategies, as well as preliminary clinical studies regarding FAP-targeted radionuclide therapy. Our qualitative summary of the literature to date can inform future research directions, medical guidelines, and optimal clinical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.